Latest News and Press Releases

SAN FRANCISCO, Oct. 21, 2025 (GLOBE NEWSWIRE) -- The NIH has awarded a new grant to Posit Science, the maker of the online BrainHQ brain exercises, to advance research, which showed in a...

The company aims to uncover molecular and cellular signatures associated with disease onset, progression, and risk, often before clinical symptoms appear.

RetinalGenix Technologies and RGEN Announce Strategic Collaboration to Advance Early Detection of Neurodegenerative, Systemic, and Retinal Diseases.

RetinalGenix Technologies Advances Home and Remote Monitoring Patent Portfolio, Positioning for the Future of Ocular and Systemic Disease Care

iPETcertum™ by Claritas, Automated Segmentation and Accurate Quantification in PET, PET-CT/MRI Scans, Receives Brazilian Clearance from ANVISA

NanoNewron awarded a $2.5 million NIH grant to develop TNF-α inhibitors engineered to cross the Blood-Brain Barrier to treat Alzheimer’s disease

Therini Bio announced the dosing of the first patient in their Phase 1b trial evaluating THN391 in Alzheimer's Disease

TORONTO, July 28, 2025 (GLOBE NEWSWIRE) --  Results from a large study announced today provides those with elevated Alzheimer’s risk a new path for changing the trajectory of their brain health. The...

APOLLO BEACH, Fla., June 13, 2025 (GLOBE NEWSWIRE) -- RetinalGenix Technologies Inc. OTCQB:RTGN (“RetinalGenix” or the “Company”), a pioneer in advanced retinal imaging and precision medicine, is...

Therini Bio raised a $39M Series A financing, bringing the Series A total to $75M, from top-tier investors to commence THN391 Ph 1b AD and DME studies